相关实验视频
Updated: Jun 23, 2025

09:06
Growth Assays to Assess Polyglutamine Toxicity in Yeast
Published on: March 5, 2012
13.6K
多重氨酸蛋白ATXN2:从其分子功能到其在疾病中的参与
Rafael G Costa1,2,3, André Conceição4,5,6,7,8, Carlos A Matos4,6
1Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal. rafael.gm.costa@gmail.com.
Cell death & disease
|June 14, 2024
概括
在ATXN2基因.
科学领域:
- 神经遗传学 神经遗传学
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- ATXN2基因编码了ATAXIN-2 (ATXN2),这是一个参与RNA代谢和细胞应激反应的蛋白质.
- 在ATXN2中,CAG的重复扩张导致多重胺 (polyQ) 通道的改变,影响蛋白质功能.
- ATXN2 功能障碍与神经退行性疾病有关,例如脊髓小脑性性性病2型 (SCA2),肌缩性侧面硬化症 (ALS) 和帕金森症.
研究的目的:
- 为了提供ATXN2功能的最新概述.
- 确定与ATXN2.2相关的病理机制.
- 介绍ATXN2相关疾病的当前治疗策略.
主要方法:
- 对ATXN2功能和相关病理学的文献综述.
- 对ATXN2相关神经退行症中的分子机制的分析.
- 对当前和新兴治疗方法的调查.
主要成果:
- 在RNA代谢,压力颗粒,内细胞,信号传递和昼夜节律中,ATXN2起着至关重要的作用.
- 在ATXN2中扩展的多Q通道会导致毒性增益或功能丧失,导致神经退行.
- SCA2病理包括自功能障碍,RNA毒性,氧化应激和破坏平衡.
结论:
- ATXN2功能障碍是几个神经退行性疾病的重要因素.
- 目前对SCA2的治疗方法是有症状的;创新的治疗方法正在开发中.
- 准ATXN2的分子通路为新的治疗干预提供了潜力.
更多相关视频
06:49Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans
Published on: December 17, 2021
2.8K
08:16Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
Published on: September 21, 2021
3.4K
相关概念视频
Translation
14.8K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
Translation Produces the Building Blocks of Life
Proteins are...
14.8K
Pleiotropy
40.4K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
40.4K
Mutations
81.8K
Overview
81.8K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
RNA Splicing
56.3K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.3K
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K